Arbutus Biopharma Corp Operating Lease, Payments
Arbutus Biopharma Corp (ABUS) reported Operating Lease, Payments of $634.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-23
- Arbutus Biopharma Corp operating lease, payments for the quarter ending 2019-12-31 was $195.00K.
- Arbutus Biopharma Corp operating lease, payments for the quarter ending 2019-09-30 was $298.00K.
- Arbutus Biopharma Corp operating lease, payments for the quarter ending 2019-06-30 was $311.00K.
- Arbutus Biopharma Corp operating lease, payments for the quarter ending 2019-03-31 was $312.00K.
- Arbutus Biopharma Corp operating lease, payments for fiscal 2025 was $634.00K, a 2.92% increase from fiscal 2024.
- Arbutus Biopharma Corp operating lease, payments for fiscal 2024 was $616.00K, a 3.01% increase from fiscal 2023.
- Arbutus Biopharma Corp operating lease, payments for fiscal 2023 was $598.00K, a 6.71% decline from fiscal 2022.
- Arbutus Biopharma Corp operating lease, payments for fiscal 2022 was $641.00K, a 1.38% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $634.00K 10-K · filed 2026-03-23 | |||
| 2024-12-31 | $616.00K 10-K · filed 2026-03-23 | |||
| 2023-12-31 | $598.00K 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $641.00K 10-K · filed 2024-03-05 | |||
| 2021-12-31 | $650.00K 10-K · filed 2023-03-02 | |||
| 2020-12-31 | $657.00K 10-K · filed 2022-03-03 | |||
| 2019-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $493.00K derived: sum of 2 quarters · filed 2021-03-04 | $804.00K derived: sum of 3 quarters · filed 2021-03-04 | $1.12M 10-K · filed 2021-03-04 |
| 2019-09-30 | $298.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $609.00K derived: sum of 2 quarters · filed 2019-11-06 | $921.00K 10-Q · filed 2019-11-06 | $921.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-06-30 | $311.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $623.00K 10-Q · filed 2019-08-05 | $623.00K derived: sum of 3 quarters · filed 2020-03-05 | $623.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-03-31 | $312.00K 10-Q · filed 2019-05-06 | $312.00K derived: sum of 2 quarters · filed 2020-03-05 | $312.00K derived: sum of 3 quarters · filed 2020-03-05 | $312.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | $0.00 10-K · filed 2020-03-05 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |